Thermal degradation behavior and kinetic modeling of green solvents-delignified biomass: a sustainable biomass-to-energy approach

The vast amount of empty fruit bunches (EFBs), which are generated in line with the huge production of crude palm oil in Malaysia, poses significant threats to the environment. In this sense, low-transition-temperature-mixtures (LTTMs) have been recognized as promising green solvents for the pretreatment of biomass as they are of low cost, easy to prepare, and environmental friendly with high delignification selectivity, which also improve the thermal degradation and hydrolysis performance of biomass. The delignification efficiency of LTTMs synthesized from malic acid-sucrose-water was investigated under various pretreatment temperatures, and the optimum temperature was identified to be 90°C. The delignified EFBs were applied in thermogravimetric analysis in order to study the effect of heating rates on their pyrolytic behaviors. Based on the differential thermogravimetric curves, the peaks of the maximum degradation temperature were moved to higher values with increasing heating rates. Iso-conversional Kissinger-Akahira-Sunose (KAS) model was applied in the kinetic modeling of the pyrolysis of delignified EFBs. The estimated activation energy for the untreated EFBs varied within the range of 42.27–254.16 kJ mol−1 while for the delignified EFBs were within the range of 57.73–262.12 kJ mol−1. This showed that the EFBs attained higher molecular stability after pretreatment using the LTTMs

Impacts of AKST on development and sustainability goals.

Assessment and analysis of AKST impacts; Agriculture productivity, production factors and consumption; impacts of akst on sustainability, through integrated technologies and the delivery of ecosystem services and public goods; Impacts of akst on livehoods, capacoty strenthening and empowerment; relationshipsbetween akst, coordination and regulatory processes among multipl3e stakeholders

Mapping deliberation: calculation, articulation and intervention in the politics of organ transplantation

This paper reflects on the aims and outcomes of an innovative methodology of participatory technology appraisal, called Deliberative Mapping, which seeks to contribute to theoretical debates and practical experimentation around what it might mean to bring the technosciences into democracy. Deliberative Mapping is a hybrid methodology, involving both calculative and deliberative processes, which seeks to map the entanglements of biotechnological imbroglios, and translate these connections into the contexts of decision-making. Through application to the case study of organ transplantation, these procedures of calculation and articulation are critically examined, exploring their aim to reduce asymmetries between scientific, political, economic and other framings of the issue and their operation in contexts already complexly structured through existing power relations, which indicate the challenge of co-fabricating these experimental forms of intervention into political facts

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

Immune evasion is a hallmark of cancer. Losing the ability to present neoantigens through human leukocyte antigen (HLA) loss may facilitate immune evasion. However, the polymorphic nature of the locus has precluded accurate HLA copy-number analysis. Here, we present loss of heterozygosity in human leukocyte antigen (LOHHLA), a computational tool to determine HLA allele-specific copy number from sequencing data. Using LOHHLA, we find that HLA LOH occurs in 40% of non-small-cell lung cancers (NSCLCs) and is associated with a high subclonal neoantigen burden, APOBEC-mediated mutagenesis, upregulation of cytolytic activity, and PD-L1 positivity. The focal nature of HLA LOH alterations, their subclonal frequencies, enrichment in metastatic sites, and occurrence as parallel events suggests that HLA LOH is an immune escape mechanism that is subject to strong microenvironmental selection pressures later in tumor evolution. Characterizing HLA LOH with LOHHLA refines neoantigen prediction and may have implications for our understanding of resistance mechanisms and immunotherapeutic approaches targeting neoantigens. Video Abstract [Figure presented] Development of the bioinformatics tool LOHHLA allows precise measurement of allele-specific HLA copy number, improves the accuracy in neoantigen prediction, and uncovers insights into how immune escape contributes to tumor evolution in non-small-cell lung cancer

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

The early detection of relapse following primary surgery for non-small-cell lung cancer and the characterization of emerging subclones, which seed metastatic sites, might offer new therapeutic approaches for limiting tumour recurrence. The ability to track the evolutionary dynamics of early-stage lung cancer non-invasively in circulating tumour DNA (ctDNA) has not yet been demonstrated. Here we use a tumour-specific phylogenetic approach to profile the ctDNA of the first 100 TRACERx (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy (Rx)) study participants, including one patient who was also recruited to the PEACE (Posthumous Evaluation of Advanced Cancer Environment) post-mortem study. We identify independent predictors of ctDNA release and analyse the tumour-volume detection limit. Through blinded profiling of postoperative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients who are very likely to experience recurrence of their lung cancer. Finally, we show that phylogenetic ctDNA profiling tracks the subclonal nature of lung cancer relapse and metastasis, providing a new approach for ctDNA-driven therapeutic studies

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Design and flight test of a civil unmanned aerial vehicle for maritime patrol: the use of 3D-printed structural components

This paper describes the design of the “Spotter” unmanned aerial vehicle, developed by the University of Southampton as part of the 2SEAS-3i European Interreg project. Spotter is a twin engine, 4m wing span, fixed-wing aircraft which has been designed to perform long-endurance, all-weather patrol missions in coastal and maritime environments. Reliability and safety have been among the strongest design drivers of this project; Spotter is able to survive the failure of one engine and of any single control surface. A modular approach has been adopted for the payload unit in order to allow the users to rapidly interchange the sensors required to perform different missions.One of the most innovative aspects of Spotter is the extensive use of the Selective Laser Sintering (SLS) technology (also known as 3D printing) for many of the components of its airframe. By eliminating tooling and manual labour, the 3D printing technology allows the designer to produce complex and high-performance structures at a relatively low cost and within hours of the completion of the design. Spotter and a sub-20kg version, codenamed 2SEAS-20, have undergone an extensive flight test campaign, totalling hundreds of autonomous flights (including autonomous take-off and landings) and many flight hours. This has provided the opportunity to test the reliability and robustness of the system and to gain a deeper insight into the opportunities and problems presented by the use of 3D printed structures for large airframe components